share_log

B. Riley Securities Initiates Coverage On Nektar Therapeutics With Buy Rating, Announces Price Target of $4

B. Riley Securities Initiates Coverage On Nektar Therapeutics With Buy Rating, Announces Price Target of $4

b. Riley证券公司对内克塔治疗进行覆盖评级,给予买入评级,并宣布目标价为4美元
Benzinga ·  01/08 12:37  · 评级/大行评级

B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

Riley证券的分析师Mayank Mamtani对内克塔治疗(纳斯达克:NKTR)首次评级为买入,并宣布价格目标为4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发